Skip to main content

Editas Medicine, Inc 10-Q for FY2026 Q3

Editas Medicine, Inc. (EDIT)

10-Q 2026-11-09 For: 2026-09-30
View Original
Added on November 09, 2026

About this 10-Q

Editas Medicine, Inc filed this 10-Q on November 9, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Editas Medicine received approval in October 2026 to initiate the Strive trial of EDIT-401 in Australia, with dosing on track for 2026. Net loss was $66.6 million for the nine months ended September 30, 2026, versus $154.4 million in 2025. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$10.37M
up 37.4% from $7.54M a year earlier
Net loss
$23.39M
compared with a net loss of $25.12M a year earlier
Diluted EPS
-$0.15
compared with -$0.28 a year earlier